Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism USA - English APAC - English
Tags:
Phase 1
HANGZHOU, China and SAN FRANCISCO, July 11, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in Molecular Metabolism.
Ecnoglutide is a novel, fatty acid-conjugated long-acting GLP-1 analog consisting of only natural amino acids, which simplifies the manufacturing process compared to some other GLP-1 analogs. In vitro, ecnoglutide showed potent activity that is biased towards cAMP induction over GLP-1 receptor internalization. In rodent models, ecnoglutide showed significant improvements in glycemic control and body weight reduction compared to semaglutide. In a Phase 1 clinical study, ecnoglutide was found to be generally safe and well tolerated with pharmacokinetic properties supporting once-weekly subcutaneous injections.
The full publication is available online at:
https://doi.org/10.1016/j.molmet.2023.101762
Ecnoglutide is currently being evaluated in Phase 3 clinical trials for the treatments of type 2 diabetes and obesity in China.
About ecnoglutide (XW003)
Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide is a novel, biased, long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in Phase 1 and Phase 2 clinical studies and is currently in multiple Phase 3 trials.
About Sciwind
Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog ecnoglutide (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), and oral small molecule GLP-1 receptor agonist XW014 (Phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com.
SOURCE Hangzhou Sciwind Biosciences Co., Ltd.
More news releases in similar topics
Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!
Cision Distribution 888-776-0942
from 8 AM - 9 PM ET
